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Correspondence: 
The N-methyl-D-aspartate receptor antagonist ketamine is the most attractive 
antidepressant therapy for treatment-resistant patients with major depressive disorder 
(MDD) and bipolar disorder (BD) (1, 2). A single subanesthetic dose (0.5 mg/kg) of 
ketamine produces a rapid antidepressant effect in two-thirds of these patients, which 
can last for over a week (3, 4). However, biomarkers able to differentiate between 
responding and non-responding patients have yet to be identified (3, 5).  
Depression and suicidal ideation in patients with MDD are associated with 
increased levels of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and 
tumor necrosis factor (TNF)-α (6-9). Inhibition of these cytokines improves 
depressive symptoms and increases the response to antidepressant medication (7-9). 
An obvious conclusion of these data is that inflammatory processes are integral to the 
pathophysiology of MDD, and therefore these pro-inflammatory cytokines could act 
as potential biomarkers, capable of predicting a treatment response to antidepressants. 
A recent review proposed two primary mechanisms underlying ketamine’s 
antidepressant activity, namely its direct effect on inflammatory cytokines and 
involvement of the tryptophan (TRY) - kynurenine (KYN) pathway (10). In this study, 
we evaluated the relationship between pro-inflammatory cytokines and antidepressant 
responses to ketamine, in treatment-resistant patients with MDD. We also examined 
whether baseline levels of pro-inflammatory mediators could be used as potential 
predictors for ketamine’s antidepressant efficacy. 
This study was approved by the Ethics Committee of the PLA 102nd Hospital, 
Changzhou, China. A total of 16 inpatients who fulfilled the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) criteria were recruited to the study. Recruits 
were antidepressant-free for at least two weeks prior to study start, ensuring that there 
were no residual effects of previous antidepressant treatment on our biomarkers of 
interest. Participants were administered an intravenous infusion of 0.5 mg/kg 
ketamine, over 40 minutes. Twenty-four matched, healthy volunteers were enrolled as 
controls, and required to have no present or past history of any DSM-IV Axis I or 
Axis II diagnosis. Depressive symptoms were evaluated at 60 minutes (baseline) prior 
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to the ketamine infusion, and then at 110 minutes and 230 minutes, continuing at time 
points 1, 3, and 7 days post-infusion, using the 17-item Hamilton Depression Rating 
Scale (HDRS), and Montgomery-Åsberg Depression Rating Scale (MADRS). Patients 
exhibiting a 50% or greater reduction in MADRS scores were classified as ketamine 
responders (n=12), while non-responders (n=4) were defined as having a less than 
50% improvement. Venous blood samples were collected to determine the levels of 
serum IL-1β, IL-6 and TNF-α by radioimmunoassay, and kynurenine (KYN) and 
tryptophan (TRP) by high-performance liquid chromatography at the aforementioned 
time-points. The controls were not re-evaluated after their initial baseline visit.  
At baseline, serum levels of IL-1β and TNF-α in both responder and 
non-responder groups were significantly higher than those of the control group 
(Figure 1). Also at baseline, serum levels of IL-1β and IL-6 in the responder group 
were significantly higher than those of the control and non-responder groups. Levels 
of IL-6 did not differ between control and non-responder groups. Serum levels of 
IL-1β showed a significant decrease at 230 minutes and 1 day post-infusion, as did 
IL-6, at 230 minutes to 3 days post-infusion in the responder group (F = 4.495, df = 
2.602, P = 0.013 for IL-1β; F = 9.450, df = 2.914, P < 0.001 for IL-6), but not in the 
non-responder group (all P > 0.05). In contrast, serum levels of TNF-α and the serum 
KYN/TRY ratio remained the same after ketamine infusion. 
Ketamine has the potential to elicit psychotomimetic and dissociative side effects, 
and abuse liability, factors which could limit its use in the clinical setting. Identifying 
novel biomarkers capable of predicting the response to ketamine will be invaluable 
for selecting suitable patients for this therapy. In this study, we found that baseline 
serum levels of IL-6 in the responder group were significantly higher than those in the 
non-responder group. This is the first study to demonstrate that serum IL-6 is a useful 
predictor of response to ketamine’s rapid antidepressant action in treatment-resistant 
patients with MDD. In conclusion, serum IL-6 levels at baseline could be a useful 
predictive biomarker to select treatment resistant patients with MDD and BD who 
would best benefit from ketamine’s rapid antidepressant action. However, further 
studies using larger sample sizes are needed to confirm this hypothesis. 
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Figure legends: 
Figure 1. Serum levels of IL-1β, IL-6, TNF-α, and the ratio of KNY/TRY in 
responder (n = 12), non-responder (n = 4), and control (n = 24) groups. The data are 
shown as the mean ± SEM. ^P < 0.05, ^^^P < 0.001 compared with healthy controls at 
baseline; #P < 0.05, ##P < 0.01 compared with non-responders at baseline (one-way 
ANOVA, followed post-hoc Bonferroni test); *P < 0.05 and **P < 0.01 compared 
with intra-group baseline levels (repeated ANOVA, followed post-hoc Bonferroni 
test). 
 
 

